About 1,825 results

ALLMedicine™ Familial Mediterranean Fever Center

Research & Reviews  641 results

Effect of Germline MEFV polymorphisms on the prognosis of Japanese children with cancer...
Oncology Hasegawa M, Fukushima H et. al.

May 14th, 2022 - MEFV is the gene responsible for familial Mediterranean fever (FMF). It encodes pyrin, which controls inflammation; Besides, previous studies have reported that some germline MEFV variants were associated with tumour susceptibility. The loci of 12...

Familial Mediterranean Fever: How to Interpret Genetic Results? How to Treat? A Quarter...
Current Rheumatology Reports; Batu ED, Basaran O et. al.

Apr 19th, 2022 - To provide an up-to-date approach to diagnosis and management of FMF patients. Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease and prototype monogenic autoinflammatory recurrent fever syndrome. Although it ...

Cardiovascular protection associated with cilostazol, colchicine and target of rapamyci...
Journal of Cardiovascular Pharmacology; Adeva-Andany MM, Fernández-Fernández C et. al.

Apr 7th, 2022 - An alteration in extracellular matrix production by vascular smooth muscle cells is a crucial event in the pathogenesis of vascular diseases such as aging-related, atherosclerosis and allograft vasculopathy. The human target of rapamycin (TOR) is ...

Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Medite...
Rheumatology International; Ozdede A, Guner S et. al.

Apr 5th, 2022 - Most of the published data relate to classical forms of rheumatic diseases (RD) and information on rare inflammatory disorders such as Behçet's syndrome (BS) and familial Mediterranean fever (FMF) is limited. We studied the frequency of side effec...

see more →

Drugs  36 results see all →

Clinicaltrials.gov  17 results

Are Mast Cells Involved in Autoinflammatory Diseases

Mar 23rd, 2022 - Autoinflammatory diseases (AID) are caused by innate immunity dysregulation and characterized by recurrent bouts of fever, frequently associated with digestive, articular or cutaneous symptoms, and sometimes ocular, auricular or neurologic inflamm...

Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19)

Mar 14th, 2022 - We aim to determine if Colchicine improves short-term outcomes in hospitalized coronavirus disease-19 (COVID-19) patients with cardiac manifestations of disease. Myocardial injury has been described in up to 30% of COVID-19 infected patients, and ...

Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever

Jan 13th, 2022 - This long-term open-label study is an extension of the core double blind, randomized, placebo-controlled study, CL04018065. It is planned that this study will include no more than 60 patients who completed the core study, where they received blind...

Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine

Oct 26th, 2021 - The study is supposed to enroll (randomize) 60 subjects with familial Mediterranean fever (FMF) with colchicine inefficacy or intolerance. Given potential withdrawal at the screening, the number of screened subjects (signed informed consent) will ...

The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.

Apr 27th, 2021 - Various anti-viral treatments are being tested in clinical trials worldwide. The World Health Organization (WHO) launched a simple,pragmatic worldwide open-label trial to test Remdesivir, Lopinavir/Ritonavir, Interferon and Hydroxychloroquine or C...

see more →

News  34 results

Does Meta-Analysis Slam the Door on Colchicine for COVID-19?

Nov 23rd, 2021 - Adding colchicine (Colcrys) to current standard of care COVID treatment was not associated with any benefit, but it was associated with more adverse events, a meta-analysis found. In a pooled analysis involving six intention-to-treat studies, colc...

Emerging Biomarkers for Targeted Agents Show Promise in NSCLC

Dec 4th, 2020 - Alex A. Adjei, MD, PhD As advancing technologies and novel agents continue to expand treatment strategies in non—small cell lung cancer (NSCLC), the quest to develop more effective therapies targeting NTRK, RET, MET, BRAF, and HER2 is underway, s...

FDA Approves Canakinumab (Ilaris), First Drug for Adult-Onset Still's Disease

Jun 19th, 2020 - The Food and Drug Administration has expanded the indications for canakinumab (Ilaris) to include all patients with active Still's disease older than 2 years, adding adult-onset Still's disease (AOSD) to a previous approval for juvenile-onset Stil...

NHS England Funds 'Life-Changing' Treatment for Periodic Fever Syndromes

Mar 4th, 2020 - NHS England is funding a 'life-changing treatment' for certain individuals with periodic fever syndromes (PFS), a group of rare conditions characterised by fever, joint pains and swelling. Patients with PFS often experience inflammatory 'flares' i...

Patients with CAPS still improving on long-term canakinumab
Ted Bosworth

Jun 14th, 2019 - MADRID – An observational study that includes adults and children with cryopyrin-associated periodic syndromes and related diseases has provided real-world evidence that clinical improvement accrues on canakinumab (Ilaris) years after treatment wa.

see more →

Patient Education  2 results see all →